Last update 19 Mar 2026

GIA-632

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
GIA-632
Target
IL-15
Action
inhibitors
Mechanism
IL-15 inhibitors(Interleukin-15 inhibitors)
Therapeutic Areas
Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [1]
Active Indication
Nonsegmental vitiligoDermatitis, Atopic
Inactive Indication-
Originator Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
Active Organization
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.Novartis Pharma AGChina Novartis Institutes for BioMedical Research Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with GIA-632
NCT07431177
/ RecruitingPhase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
NCT07220577
/ RecruitingPhase 2
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
100 Clinical Results associated with GIA-632
Login to view more data
100 Translational Medicine associated with GIA-632
Login to view more data
100 Patents (Medical) associated with GIA-632
Login to view more data
100 Deals associated with GIA-632
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonsegmental vitiligoPhase 2
United States
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
09 Mar 2026
Nonsegmental vitiligoPhase 2
Australia
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
09 Mar 2026
Nonsegmental vitiligoPhase 2
Canada
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
09 Mar 2026
Dermatitis, AtopicPhase 2
United States
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
Bulgaria
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
Canada
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
Czechia
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
France
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
Germany
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Dermatitis, AtopicPhase 2
Malaysia
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
10 Nov 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free